论文部分内容阅读
目的:探讨培高利特对早期帕金森病患者纹状体多巴胺能神经元的影响以及改善患者肢体运动能力的作用。方法:选择2001-04/2001-12在上海长海医院神经内科帕金森病专病门诊就诊、未经抗帕金森病药物治疗、具有单侧肢体运动徐缓、震颤、强直、特殊姿势的早期帕金森病患者22例为研究对象;男14例,女8例;年龄55～70岁。所有患者均书面同意参加该试验,整个试验过程中能坚持服用单一药物治疗,未经同意不能改动治疗方案。将患者随机分为安慰剂组11例和培高利特组11例。安慰剂组给予苯海索治疗,培高利特组给予培高利特治疗。苯海索、培高利特起始日剂量均为0.05mg。入组第1周时,每日服用1次;以后每周增加1粒,经过1个月左右达到日剂量0.25mg,此后维持剂量恒定(该剂量苯海索抗帕金森病作用不明显,故安慰剂组可称为帕金森病自然变性组)。①观察两组治疗前及治疗后13个月纹状体99Tcm-2β-犤N’双(2-硫乙基)乙撑二胺基犦甲基,3β-(4氯苯基)托烷单光子发射计算机断层扫描特异性摄取值百分率的变化,评估纹状体多巴胺神经元的变性数量。②观察治疗前,治疗后6,13个月时帕金森病评定量表变化,评估培高利特对肢体运动功能障碍的改善作用。结果:最终进入结果分析的帕金森病患者22例。①治疗13个月后,安慰剂组和培高利特组患者起?
Objective: To investigate the effect of pergolide on striatal dopaminergic neurons in patients with Parkinson’s disease in the early stage and to improve limb motility in patients. Methods: Patients with Parkinson ’s disease in the Department of Neurology, Shanghai Changhai Hospital from April 2001 to December 2001 were treated without Parkinson’ s disease, and were treated with Parkinson ’s disease, including unilateral limb bradykinesia, tremor, rigidity and special posture. Twenty-two patients were studied. There were 14 males and 8 females, aged 55-70 years. All patients agreed in writing to participate in the trial, throughout the trial can insist on taking a single drug treatment, without consent can not change treatment options. Patients were randomized to placebo in 11 patients and pergolide in 11 patients. The placebo group was given trihexyphenidyl and the pergolide group was given pergolide. Benhaisol, Pegasol starting dose of 0.05mg. The first week into the group, taking 1 times a day; after a week increase of 1, after about 1 month to reach a daily dose of 0.25mg, thereafter to maintain a constant dose (the dose of benzene anti-Parkinson’s disease is not obvious, so Placebo group may be referred to as Parkinson’s disease naturally degenerative group). ①The levels of 99Tcm-2β- 犤N’-bis (2-sulfoethyl) ethylenediamine 犦methyl, 3β- (4-chlorophenyl) tropane monohydrate in the striatum before and after treatment for 13 months Changes in percentage of photon emission computed tomography specific uptake to assess the number of degeneration of striatal dopamine neurons. ② Observed before treatment, 6,13 months after treatment Parkinson’s disease rating scale changes, to evaluate the role of pergolide to improve limb motor dysfunction. Results: Twenty-two patients with Parkinson’s disease eventually entered the result analysis. ① After 13 months of treatment, patients in the placebo and pergolide groups started?